Kalvista Pharmaceuticals (NASDAQ:KALV) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a hold rating to a buy rating in a report released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $20.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “

KALV has been the subject of several other reports. ValuEngine cut Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Needham & Company LLC raised their price objective on Zuora from $27.00 to $30.00 and gave the stock a strong-buy rating in a research note on Wednesday, March 20th. Roth Capital restated a buy rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. Finally, BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Kalvista Pharmaceuticals has an average rating of Buy and an average price target of $29.40.



Shares of NASDAQ:KALV opened at $17.31 on Wednesday. Kalvista Pharmaceuticals has a 52-week low of $7.95 and a 52-week high of $34.92. The stock has a market capitalization of $298.60 million, a PE ratio of -11.31 and a beta of 2.12. The business has a 50-day moving average price of $20.59.

In related news, insider Edward P. Feener sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $24.92, for a total transaction of $99,680.00. Following the sale, the insider now directly owns 100,950 shares of the company’s stock, valued at $2,515,674. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $24.80, for a total value of $248,000.00. Following the sale, the chief executive officer now directly owns 258,810 shares in the company, valued at $6,418,488. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,501 shares of company stock worth $645,553. 38.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC acquired a new stake in Kalvista Pharmaceuticals during the first quarter worth about $21,036,000. Geode Capital Management LLC grew its holdings in Kalvista Pharmaceuticals by 30.6% during the fourth quarter. Geode Capital Management LLC now owns 83,881 shares of the specialty pharmaceutical company’s stock worth $1,656,000 after acquiring an additional 19,636 shares during the period. Polar Capital LLP acquired a new stake in Kalvista Pharmaceuticals during the fourth quarter worth about $1,558,000. Barclays PLC grew its holdings in Kalvista Pharmaceuticals by 88,319.7% during the fourth quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 62,707 shares during the period. Finally, Laurion Capital Management LP grew its holdings in Kalvista Pharmaceuticals by 94.9% during the first quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock worth $1,685,000 after acquiring an additional 28,670 shares during the period. 80.64% of the stock is currently owned by hedge funds and other institutional investors.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: How does a reverse stock split work?

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.